104 related articles for article (PubMed ID: 27153872)
1. Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.
Zannoni GF; Improta G; Pettinato A; Brunelli C; Troncone G; Scambia G; Fraggetta F
J Clin Pathol; 2016 Dec; 69(12):1088-1092. PubMed ID: 27153872
[TBL] [Abstract][Full Text] [Related]
2. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
4. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
[TBL] [Abstract][Full Text] [Related]
5. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
[TBL] [Abstract][Full Text] [Related]
6. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
7. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
8. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
9. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
10. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
Kwon MJ; Lee SE; Kang SY; Choi YL
Pathol Res Pract; 2011 Dec; 207(12):762-8. PubMed ID: 22070922
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutations in sinonasal cancer.
López F; García Inclán C; Pérez-Escuredo J; Alvarez Marcos C; Scola B; Suárez C; Llorente JL; Hermsen MA
Oral Oncol; 2012 Aug; 48(8):692-7. PubMed ID: 22459936
[TBL] [Abstract][Full Text] [Related]
12. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients.
Joutei HAH; Marchoudi N; Mahfoud W; Sadaoui I; Fechtali T; Benomar H
Arab J Gastroenterol; 2018 Dec; 19(4):155-158. PubMed ID: 30503528
[TBL] [Abstract][Full Text] [Related]
13. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
14. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
15. Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.
Steffensen KD; Waldstrøm M; Grove A; Lund B; Pallisgård N; Jakobsen A
Int J Gynecol Cancer; 2011 Dec; 21(9):1592-600. PubMed ID: 21926912
[TBL] [Abstract][Full Text] [Related]
16. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
17. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer.
Symvoulakis EK; Zaravinos A; Panutsopulos D; Zoras O; Papalambros E; Sigala F; Spandidos DA
Int J Biol Markers; 2007; 22(1):12-8. PubMed ID: 17393356
[TBL] [Abstract][Full Text] [Related]
18. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
19. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract][Full Text] [Related]
20. Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma.
Nascimento FP; Cardoso MG; Lindsey SC; Kunii IS; Valente FO; Kizys MM; Delcelo R; Camacho CP; Maciel RM; Dias-Da-Silva MR
Mol Med Rep; 2016 Feb; 13(2):1653-60. PubMed ID: 26718898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
